Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

Alice Huertas; David Montani; Laurent Savale; Jérémie Pichon; Ly Tu; Florence Parent; Christophe Guignabert; Marc Humbert

doi:10.1183/13993003.01634-2020

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

Eur Respir J. 2020 Jul 30;56(1):2001634. doi: 10.1183/13993003.01634-2020. Print 2020 Jul.

Authors

Alice Huertas^{1

2

3}, David Montani^{4

2

3}, Laurent Savale^{4

2

3}, Jérémie Pichon^{4

2

3}, Ly Tu^{4

2}, Florence Parent^{4

2

3}, Christophe Guignabert^{4

2}, Marc Humbert^{4

2

3}

Affiliations

¹ Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France alice.huertas@inserm.fr.
² INSERM UMR_S 999 «Pulmonary Hypertension: Pathophysiology and Novel Therapies», Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
³ Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
⁴ Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.

Abstract

Endothelial cell dysfunction and impaired microcirculatory function contribute markedly to life-threatening complications of COVID-19, such as venous thromboembolic disease and multiple organ involvement https://bit.ly/3cZMjKV

Publication types

Editorial
Comment

MeSH terms

Betacoronavirus
COVID-19
Coronavirus Infections*
Endothelial Cells
Humans
Intensive Care Units
Pandemics*
Pneumonia, Viral / epidemiology*
SARS-CoV-2
Venous Thromboembolism*